顺铂联合腹腔持续热灌注治疗胃癌腹腔转移癌性腹水的临床研究

Clinical Study of Cisplatin Combined with Continuous Hyperthermic Peritoneal Perfusion in the Treatment for Metastatic Ascites with Gastric Cancer

[目的]观察顺铂(DDP)联合持续热灌注治疗胃癌腹腔转移腹水的疗效及不良反应。[方法]60例胃癌腹水患者分为顺铂联合腹腔持续热灌注组(治疗组)和单纯顺铂腹腔灌注化疗组(对照组),每组各30例。对两组生存期、控制腹水的近期疗效、不良反应进行观察。[结果]治疗组和对照组的中位生存期分别为10.2个月和5.9个月,有效率分别为76.7%和53.3%(P<0.05),治疗组不良反应无加重。[结论]DDP联合腹腔持续热灌注治疗胃癌腹水,能够提高疗效,延长生存期而不增加不良反应,值得进一步推广。

[Purpose] To investigate the efficacy and toxicity of cisplatin combined with continuous hyperthermic peritonal perfusion （CHPP） in the treatment for metastatic ascites with gastric cancer-induced peritoneal effusion. [Methods] Sixty patients with metastatic ascites were divided into two groups： treatment group （received cisplatin and CHPP） and control group （received cisplatin alone）.The survival,short-term response,quality of life and side effects were observed. [Results] The median survival of the treatment group and control group were 10.2 months and 5.9 months;and the response rates,76.7% and 53.3%（P 0.01）respectively. The incidence rates of side effects were similar between the two groups. [Conclusions] Cisplatin combined with CHPP can increase treatment response and improve survival without increasing side effects in patients with metastatic ascites with gastric cancer.